Results 201 to 210 of about 189,595 (350)

Non-invasive dentistry method for clinical determination of bleeding time: evaluation in subjects with and without direct oral anticoagulant therapy. [PDF]

Thromb J
Pfützner A, Zimmermann A, Wendling S, Jantz J, Shing RNK, Pilot J, Gillen D, Invest JCF, Thomé N, Ernst CP, Willershausen B.   +10 more
europepmc   +1 more source

Anticoagulant Therapy for Central Nervous System Venous Sinus Thrombosis - A Retrospective Study [PDF]

, 1999
Nicole F Parkerson, John A. Jane, Pedro A. de Alarcón   +2 more
openalex   +1 more source

MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation

ESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.
Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio, Cristiano Amarelli, Rosaria Chiappetti, Irene Mattucci, Veronica Flocco, Mahmoud Issa Rammal, Ciro Abete, Francesca Mazzella, Ciro Maiello, Pasquale Abete, Francesco Cacciatore   +10 more
wiley   +1 more source

Anticoagulant therapy and altered tissue factor expression protect against experimental placental and cerebral malaria. [PDF]

PLoS Pathog
Andrew AK, Bracken TC, Nazario-Maldonado N, Russ BN, Gonzalvo KT, Brainard BM, Mackman N, Moore JM.   +7 more
europepmc   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

ANTICOAGULANT THERAPY [PDF]

Journal of Clinical Pathology, 1962
openaire   +2 more sources

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Pharmacists' Knowledge of Abnormal Uterine Bleeding in Women on Anticoagulant Therapy: A French Survey. [PDF]

Clin Appl Thromb Hemost
Frerebeau S, Planquette B, Sarlon G, Gendron N.   +3 more
europepmc   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Long-term bleeding events post-percutaneous coronary intervention in patients with malignancy with and without anticoagulant therapy. [PDF]

Cardiovasc Interv Ther
Otsuka Y, Ishii M, Ikebe S, Tokai T, Nakamura T, Tsujita K, Akashi N, Fujita H, Nakano Y, Matoba T, Kohro T, Oba Y, Kabutoya T, Kario K, Imai Y, Kiyosue A, Mizuno Y, Nochioka K, Nakayama M, Iwai T, Miyamoto Y, Sato H, Nagai R, CLIDAS research group.   +23 more
europepmc   +1 more source